10 thus seems to regulate both chemokine production and chemokine response.
Several reports suggest that CCL 16 induces chemotaxis and adhesion by interacting with CCRI at concentrations higher than those of a typical CC chemokine (2) (3) 10) . It is uncertain whether other receptors are involved in CCL16-mediated activities. Howard et al. have suggested that CCR8 mediates monocyte chemotaxis to CCLl6. A role for CCR2 and CCR5 has also been postulated (10) (11) .
CCL 16 is chemotactic in vitro for monocytes, dendritic cells and lymphocytes (2) (3) . This role is corroborated by its potent anti-tumor activity (12) associated with recruitment of leukocytes, as shown in murine models using CCL 16-transfected adenocarcinoma cells (13) . An adenovirus encoding CCL 16 induces accumulation of T and DC at the tumor site as well as in draining lymph nodes when injected in established tumors (14) .
Chemokines modulate target cell activities other than chemotaxis, such as proliferation and cytokine production. CCL5 induces IL-2 and IL-5 production, augments proliferation and enhances expression of activation and adhesion molecules on T cells (15) (16) . CCL5, CXCLl and CXCL2 induce the expression of other chemokines and inflammatory cytokines leading to amplification of the leukocyte recruitment by a cascade mechanism (17) (18) (19) . In this study we set out to determine whether CCL 16 regulates the expression of other chemokines by monocytes, and whether its biological and chemotactic effects are modulated by IL-IO. We show that CCLl6 induces the expression of CCL2 and CXCL8 by a pertussistoxin (PTX) sensitive pathway, suggesting that the process is mediated by G-protein-coupled receptors (GPCR). In addition, we show that IL-1O augments CCLl6-induced CCL2 production and enhances the monocyte chemotactic response to suboptimal CCL 16 concentrations. This enhancement is prevented by anti-CCRI antibodies, suggesting that CCRI is the most prominent receptor mediating the monocyte response to CCLl6.
MATERIALS AND METHODS

Reagents
Human (h) recombinant (r) CCL16 and hrIL-lO, were from Pepro Tech, Inc. (London, UK). LPS (from Escherichia coli aIII :B4) and PTX were from Sigma Chemical Co (St. Louis, MO) . Anti-human CCRl, CCR2 and CCR5 monoclonal Ab (MoAb) were from R&D Systems (Minneapolis, MN). Goat Ab against CCR8 was from Alexis Biochemicals (San Diego, CA). Isotypematched controls were from R&D Systems. All reagents and media were tested with the Endotoxin kit (Sigma, St. Louis, MO) and contained less than 12 pg/ml of endotoxin.
Human peripheral blood monocytes and eel/lines
Peripheral blood mononuclear cells (PBMC) were prepared by Ficoll-Hypaque (Pharmacia Milano, Italy) gradient centrifugation from buffy coats provided by the local blood bank. Untouched monocytes were separated from PBMC by magnetic depletion ofT cells, NK cells, B cells, dendritic cells and basophils by using a cocktail of CD3, CD7, CDl9, CD45RA, CD56 and anti-IgE antibodies (Monocyte Isolation Kit, Miltenyi Biotec, Bergisch Gladbach, Germany). The resultant monocytes (95% CDI4+ cells, as assessed by flow cytometry) were cultured in RPMI 1640 (Life Technologies, Rockville, MD) containing 100 U/ml penicillin, 100 ug/ml streptomycin, 2 mM L-glutamine, 20 mM HEPES (Life Technologies), and 10 % heat-inactivated FCS (HyClone Lab, Logan, UT). HEK-293 cells transfected with CCRI and CCR8 (kind gift from Dr. Zack Howard, Laboratory of Molecular Immunoregulation, Division of Basic Science, National Cancer Institute, Frederick, MD) were maintained in DMEM (Life Technologies) containing 10 % heat-inactivated FCS (HyClone Lab) in the presence of 400 ug/ml Geneticin (Life Technologies).
Reverse transcription-polymerase chain reaction (RT-peR) analysis
Total RNA was purified with TRIzol (Gibco/lnvitrogen Milano, Italy) according to the manufacturer's instructions. cDNA synthesis was performed with 2 ug of RNA in a total volume of 20 III containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCI2' 0.1 M OTT, 40 U RNaseout inhibitor, 0.5 ug of oligo (dt), 0.5 mM each dNTPs and 200 U of SuperScript II reverse transcriptase (Life Technologies). The reaction mixture was incubated at 42°C for 50 min and stopped at 95°C for 5 min. 2 III aliquots of cDNA were amplified in a 50 III reaction volume containing 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 1.5 mM MgCI 2 , 0.2 mM each dNTP, 50 pmol of each Prime Screen primer pair mixture (BIOSOURCE International, Camarillo, CA) and 2.5 U of Platinum Taq DNA Polymerase. The mixture was capped with 50 III of sterile mineral oil (Sigma). To ensure that equivalent amounts of cDNA were used in each reaction, PCR was also performed for p-actin from each sample, and the cDNA was adjusted to equivalent levels. The oligonucleotides used in the PCR reactions were purchased from BIOSOURCE as part of the Prime Screen Chemokine Primer Panel kit. Cycling conditions were: 2 min at 95°C, 1 min at 95°C, 1 min 30 sec at 65°C and 2 min at noc for 20 cycles. A sample (10 ul) of each PCR reaction was electrophoresed through a 1% agarose gel and visualized with ethidium bromide. Gels were photographed under UV light.
Cytokine ELISA
Monocytes (1 x 106/wells) were incubated with the indicated cytokines for different times in 48-well plates. Cell culture supernatants were assayed for cytokines by ELISA according to the manufacturer's instructions. ELISA kits for hCCL2 and hCXCL8 were from Amersham Pharmacia. ELISA kits for hCCL5, hCCLl8, hTNF-a, hIL-lO and hIL-12p70 were from R&D Systems.
Chemotaxis
Monocyte migration was evaluated with a chemotaxis microchamber technique (NeuroProbe, Pleasanton, CA), as previously described (20) . Chemoattractants, diluted in assay medium (RPMI 1640 with 1% BSA and 25 mmol/L HEPES), were placed in the lower wells of the chemotaxis chamber. A polycarbonate filter (5 ug pore size; NeuroProbe) was placed over the chemoattractants. A 50 ul aliquot of monocyte suspension at 1 x 10 6 cell/ml was placed in the upper wells.
In the experiment, monocytes were pretreated with 10 ug/ml of the MoAb to CCRl, CCR2, CCR5, CCR8 or control MoAb for 30 minutes at 37°C. The chamber was incubated at 37°C in air with 5% CO 2 for 90 min. The filters were then removed and stained with Diff-Quik (Baxter, Rome, Italy). Migrating cells in five high-power oil-immersion fields were counted. The results are expressed as chemotactic index (fold increase of cell response to stimulants over the response to assay media alone) and are representative of at least 3 experiments.
Statistics
The significance of comparisons between groups was assessed with Student's t test or by analysis of variance, as appropriate. When a difference was found between multiple treatments, the Newman-Keuls multiplecomparison test was used to identify which means were significantly different from the others at the 0.05 significance level.
RESULTS
CCL16 selectively induces CCL2 and CXCL8
production from human monocytes. CCL 16 produced by tumor-transfected cells induces a strong recruitment of leukocytes (monocytes, lymphocytes and dendritic cells) (13). Fig. 1 . Cytokine production by human monocytes stimulated with CCLl6. CCL2 and CXCL8 production was assayed by ELISA with supernatants derived from monocytes cultured for 24 hours with medium alone or supplemented with increasing concentrations ofCCLJ6 (panel A and B respectively) or with supernatants derived from monocytes cultured for the indicatedtime with mediumalone or supplemented with J j1g/ml of CCLl6 (panel C and D respectively).
Results are expressed as mean of duplicate and where vertical bars are not appreciable the SEM is smaller than the size ofthe symbols. One representative experiment of three performed is shown. ,..,
,..,
The relatively weak in vitro chemotactic activity of CCL 16 versus its potent induction of leukocyte infiltration in vivo suggests that some of its in vivo activities are mediated by secondary effectors present in the tumor microenvironment (13) .
To investigate this possibility, we incubated human monocytes with 1 ug/ml CCL 16. After 24 h, CCL 16 induced a marked increase of CCL2 and CXCL8 production (sixteen and two fold respectively), but there was no up-regulation of CCL5, CCLl8, TNF-a, IL-lO and IL-12 secretion, in comparison to LPS, one of the strongest stimuli for monocytes, used as positive control (Tab. I). Dose response experiments show that CCL 16 increased CCL2 and CXCL8 production already at 0,1 ug/ml and its effect was greatly enhanced at 1 ug/ml ( Fig.  lA and IB). CCL2 and CXCL8 production by CCL 16-stimulated monocytes arose as early as 6 h after addition of the chemokine (Fig. 1C and 1D ). The enhanced effect of CCL 16 was observed at 24 h and lasted until 48 h. CCL 16-induced CCL2 production by monocytes was inhibited by pretreatment with anti-CCLl6 Ab ( Fig. 2A ). This rules out any contribution on the part of contaminants. Moreover, boiled CCL 16 did not stimulate secretion above the control levels (data not shown).
Pertussis toxin inhibits CCL2 production in response to CCLI6.
Chemokines transmit signals via seventransmembrane domain receptors that couple to Gi and Gq class proteins (22) . To investigate the role of G proteins in the monocyte response to CCL 16, we pretreated monocytes with the Gi inhibitor PTX. The release ofCCL2 was then determined following 24 h stimulation with CCLl6. As shown in Fig. 2B , the induction of CCL2 by CCL 16 is partially prevented, suggesting that PTX-sensitive GPCR signaling is involved in the induction of CCL2 by CCL 16 in monocytes.
IL-IO enhances CCL2 production in response to
CCLl6.
Because IL-l 0 has been shown to increase CCL16 RNA expression (2), the effect ofIL-IO on CCLl6induced response in monocytes was investigated. Monocytes were treated with CCL16 in the presence or absence of IL-IO for 24 h. Supernatants were harvested and tested for CCL2 content by ELISA. To study this effect monocytes were pre-incubated with IL-l 0 for 24 h and then cultured with increasing concentrations of CCL16 (0.1 to 1 ug/ml), This pretreatment enabled monocytes to produce higher amount of CCL2 in response to all CCL16 CCL 16 consistently induced CCL2 release, despite some donor-to-donor variations (Tab. 1I).The combined treatment increased CCL2 production more than IL-IO or CCL 16 alone while CXCL8 secretion induced by CCL16 was inhibited by IL-lO, suggesting that it differentially regulates the expression of chemokines induced by CCL 16. This is a specific effect because IL-IO inhibited the production of both CCL2 and CXCL8 on LPS stimulated monocytes (Tab. II).
As shown in Fig. 3 , both CCL16 and IL-IO induced the transcript of this chemokine, but the extent of CCL2 mRNA expression was higher after treatment with CCL 16. Combined stimulation with CCL16 plus IL-IO resulted in even higher CCL2 mRNA levels. concentrations tested (Fig. 4A ). To determine whether IL-l 0 also regulates monocyte chemotaxis in response to CCL 16, monocytes were cultured for 24 h with IL-IO and their chemotactic response was evaluated against increasing concentrations of CCL16. As shown in FigAB, IL-IO pre-treatment enables monocytes to respond to CCL 16 at concentration as low as 0.1 ug/rnl, which is too low (ten times lower) to activate chemotaxis in untreated monocytes. Moreover, IL-IO-treated monocytes showed a two-fold increase of chemotaxis to CCL 16 at 1 ug/ml as compared to untreated cells. .
CCRI mediates the response of IL-IO treatedmonocyte to CCLI6.
To determine which chemokine receptor is involved in the response of IL-IO-stimulated monocytes to CCL 16, we evaluated the effect on the migratory capacity of monocytes of neutralizing antibodies directed against the identified CCL 16 receptors. This response was strongly inhibited after incubation with anti-CCRl, whereas anti-CCR8, anti-CCR2 and anti-CCR5 had no effect (Fig. 5 ). Combination of anti-CCRI with anti-CCR8 ( Fig. 5 ) or the other neutralizing antibodies (data not shown) did not increase the inhibitory effect of anti-CCRI alone, suggesting that the response of IL-I O-treated monocytes is mainly mediated by CCRI. Neutralizing MoAb against CCRl, CCR2, CCR5 and CCR8 significantly inhibited monocytes chemotaxis induced by their specific ligands, CCL3, CCL2, CCL4 and CCL 1 respectively.
CCL16 induces CCL2 secretion by CCR1transfected HEK-293.
To determine which receptors are responsible for CCLl6-induced chemokine production, we assessed the ability of human embryonic kidney (HEK) 293 cells, stably transfected to express either CCRI or CCR8, to respond to CCLI6. These cells display a baseline production of CCL2 (Fig. 6A ) and CXCL8 ( Fig 6B) that was only stimulated by CCLl6 in those expressing CCR I. These results indicate CCR I as a major receptor that mediates chemokine induction by CCLl6.
DISCUSSION
CCLl6 is a CC chemokine displaying chemotactic activity for monocytes and dendritic cells. In this report we demonstrate that it induces the production of CCL2 and CXCL8, but not that of the pro-and anti-inflammatory cytokines such as TNF-a, IL-12, and IL-I 0 in monocytes. These results indicate that CCL16 also regulates gene expression in monocytes. This effect is detectable at 0, I ug/ml for CCL2 production, but a concentration 10-fold more is needed to induce CXCL8 secretion and gene expression, in agreement with previous chemotaxis studies. CCL 16,  in fact, displays a significant chemotactic activity for monocytes at a concentration that is 6-12 times greater than that required for a typical CC chemokine. The possibility that this required an unusually high concentration due to contaminants was ruled out by the use ofneutralizing anti-CCLl6 antibody. CCL 16 attracts monocytes and induces calcium mobilization through a G-protein-coupled receptor (10) (11) . Our results show that PTX partially inhibits CCLl6-induced CCL2 production by monocytes, indicating the involvement of a Gi protein. However, CCL2 production by CCL 16 may be mediated by both PTX-dependent and PTX-independent pathways, as previously shown for CCL5 stimulation on T cell and for CCLll suppression of CXCL8 secretion on endothelial cells (15, 23) . Our results are in agreement with the growing evidence that chemokines regulate functions other than cell adhesion and migration, including cell proliferation and cytokine production. CCL5, for example, induces chemokine and cytokine release in monocytes, dendritic cells and astrocytes (17) (18) (19) 21) . These reactions may serve to extend chemokine production and prolong the inflammatory response. We have previously reported that the release of CCL 16 by engineered tumor cells results in the rejection oftransplanted tumors in syngeneic mice by promoting an impressive influx of monocytes, dendritic cells, T cells and granulocytes to the tumor site (13) . This observation was surprising because there is evidence that CCL 16 is not directly chemotactic in vitro for granulocytes (2) (3) . Our results suggest that high local concentrations of CCL 16 stimulate downstream mediators such as CCL2 and CXCL8, which are known to induce granulocyte, monocyte and lymphocyte recruitment and can amplify tumor infiltration. Locally produced cytokines or bacterial products may regulate the kinetics and composition of the leukocyte infiltrate by affecting both chemokine production and receptor expression. In this regard the predominant effect of IL-IO is to reduce inflammation by inhibiting chemokine production (24) (25) (26) . However, IL-10 has a peculiar effect on CCL2 production, since its regulation depends on the environment (6-7). Our results confirm the previous observation that IL-10 induces CCL2 production by resting blood monocytes, but inhibits CCL2 production in response to LPS. When combined with CCL 16, which induces both CCL2 and CXCL8, IL-10 greatly enhances CCL2 production induced by CCL 16, while inhibits that of CXCL8. IL-10 may play a role in the transition from neutrophilic to mononuclear inflammation by amplifying CCLl6mediated monocyte recruitment and by differentially affecting CCL2 and CXCL8 expression.
CCL2 induction by CCLl6 and the enhancing effect of IL-10 are associated with CCL2 mRNA expression, as shown by RT-PCR. The mechanisms involved in the regulation of CCL2 expression by IL-10 are still under investigation. It is likely that different stimuli such as LPS and CCL 16 modulate the intracellular signaling pathways in monocytes, thereby changing their responsiveness to IL-IO. Further studies on signaling pathways triggered by IL-10 and on their interactions with CCL 16 and LPS are required to clarify this issue.
We report here that IL-10 also increases the sensitivity of monocytes to CCL 16, as suggested by the observation that stimulation with as low as 10-100 ng/ml of CCL 16 is sufficient to induce both chemotaxis and CCL2 release by IL-1 O-stimulated monocytes.
The ability of IL-10 to up-regulate the expression of CCR 1, CCR2 and CCR5 may partly account for the increased biological response of target cells to CCLl6 (9, 27) . Competitive binding studies to human monocytes have shown that CCL 16 partially competes with CCL4, CCLl and CCL5, indicating that CCR 1, CCR5 and CCR8 are candidate receptors for CCL16. Further studies of cell lines stably transfected with CCR 1 or CCR8 have demonstrated that CCL 16 is a low-affinity functional ligand for these receptors (10) . However, studies of the pre-B mouse cell line L1.2 transfected with different GPCRs demonstrate that CCR8-transfected cells fail to respond to CCL 16 and suggest CCR2 and CCR5 as alternative receptors for CCL16 (11) . These studies imply a complex pattern of receptor usage by CCL 16, which may depend on the cell system employed.
Our observation that blocking anti-CCR1 mAb inhibits up to 80% of the chemotactic response by IL-10-treated monocytes to CCL 16, whereas anti-CCR8, anti-CCR5 and anti-CCR2 mAb had a negligible effect, suggests that CCR1 is the principal Gicoupled GPCR that mediates both CCL 16 chemotactic activity and its ability to regulate CCL2 gene expression in IL-1O-treated cells. In a previous work we demonstrated that BX47l, a CCRI antagonist, inhibits angiogenic properties of CCL 16, while blocking of CCR8 or desensitising CCR2 did not abolish-endothelial activation (28) .
This hypothesis is further supported by experiments performed with HEK293 cells stably transfected with chemokine receptors. HEK293-CCRl, but not HEK293-CCR8 cells responded to CCL 16 stimulation with secretion of CCL2 and CXCL8. However, our finding that IL-l 0 treatment of monocytes has opposite effects on CXCL8 and CCL2 expression, suggests that IL-l 0 might also act at a post-receptor level by modulating the activation status and/or the expression of signaling molecules or transcription factors required for CXCL8 and CCL2 expression,
The biological role of CCL 16 has not been studied in detail. Our results indicate that it may amplify leukocyte recruitment by inducing a cascade of chemokines. We hypothesize that prevalent secretion of IL-lO in tissues in the presence of CCL 16 could lead to increased inflammation due to CCL 16 expression, augmented monocyte responsiveness to CCL 16 and upregulation of CCL2 secretion. Indeed, transgenic expression of IL-10 in the lung, although inhibiting LPS-induced inflammation, also induces T and B cell infiltration and fibrosis (29) . This finding is also in line with studies demonstrating that transgenic IL-lO causes lymphocyte infiltration in the salivary glands and pancreas (30) (31) . The leukocyte infiltrate driven by CCL 16 and CCL2 secretion in the presence of IL-10 could play a role in wound healing or chronic inflammation.
The largely restricted CCL 16 expression in the liver, suggests that this chemokine may playa role in hepatic vascular formation during development and in angiogenesis associated to hepatic diseases (28) . Because IL-10 is expressed in hepatic injury (32) (33) (34) , it may synergize with CCL 16 in the liver microenvironment to produce CCL2. Clinical and experimental studies have demonstrated that hepatic levels of CCL2 are markedly enhanced during various types of liver injury (35) (36) . It has been shown that IL-lO (37-38) and CCL16 (38) are overexpressed in mucosa ofpatients with active ulcerative colitis. Immature DC in the lamina propria are associated with IL-lO in the T cell rich area. Furthermore, most of the lamina propria-infiltrating macrophages were shown to strongly express CCL 16 (38) . Study of CCL16 expression in pathological conditions and diseases characterized by prolonged inflammation or associated with high levels of IL-10 secretion will be required to elucidate the biological significance of the correlation between CCL16 functional response and IL-10 secretion.
